- Home
- ACXP vs RNXT Comparison
ACXP vs RNXT Comparison
Compare ACXP & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACXP | RNXT |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 36.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACXP | RNXT |
|---|---|---|
| Price | $2.92 | $1.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $143.67 | $7.75 |
| AVG Volume (30 Days) | 86.7K | ★ 202.4K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $928,000.00 |
| Revenue This Year | N/A | $2,795.35 |
| Revenue Next Year | N/A | $272.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.44 | $0.70 |
| 52 Week High | $25.00 | $1.69 |
Technical Indicators
Market Signals| Indicator | ACXP | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 38.16 | 61.75 |
| Support Level | $2.44 | $0.84 |
| Resistance Level | $3.63 | $0.92 |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 35.86 | 96.30 |
Price Performance
Historical ComparisonAbout ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.